• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间质性肺疾病的可治疗特征:一篇叙述性综述

Treatable traits in interstitial lung disease: a narrative review.

作者信息

Harrison Megan, Lawler Chloe, Lake Fiona, Navaratnam Vidya, Fermoyle Caitlin, Moodley Yuben, Corte Tamera J

机构信息

Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

出版信息

Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251335774. doi: 10.1177/17534666251335774. Epub 2025 May 3.

DOI:10.1177/17534666251335774
PMID:40317250
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12049629/
Abstract

The interstitial lung diseases (ILDs) are a heterogeneous and complex group of diseases. The treatable trait (TT) model represents a shift in ILD management, away from traditional diagnostic labels towards a more individualised, trait-focused approach. This review explores the application of the TT paradigm to ILD, identifying key traits across the aetiological, pulmonary, extrapulmonary and behavioural domains. By addressing these traits, the TT model offers a framework to improve outcomes in ILD through multidisciplinary management with a precision medicine focus. Further research is necessary to evaluate the overall impact of this TT model on ILD care.

摘要

间质性肺疾病(ILDs)是一组异质性且复杂的疾病。可治疗特征(TT)模型代表了ILD管理方式的转变,从传统的诊断标签转向更个体化、以特征为重点的方法。本综述探讨了TT范式在ILD中的应用,确定了病因、肺部、肺外和行为领域的关键特征。通过解决这些特征,TT模型提供了一个框架,以精准医学为重点,通过多学科管理改善ILD的治疗效果。有必要进行进一步研究以评估该TT模型对ILD护理的总体影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6df2/12049629/11a72fea101c/10.1177_17534666251335774-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6df2/12049629/0e4ecfa1a26e/10.1177_17534666251335774-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6df2/12049629/11a72fea101c/10.1177_17534666251335774-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6df2/12049629/0e4ecfa1a26e/10.1177_17534666251335774-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6df2/12049629/11a72fea101c/10.1177_17534666251335774-fig2.jpg

相似文献

1
Treatable traits in interstitial lung disease: a narrative review.间质性肺疾病的可治疗特征:一篇叙述性综述
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251335774. doi: 10.1177/17534666251335774. Epub 2025 May 3.
2
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease.可治疗特征:间质性肺病的综合精准医疗方法。
Eur Respir J. 2023 Jul 27;62(1). doi: 10.1183/13993003.00404-2023. Print 2023 Jul.
3
Walking the path of treatable traits in interstitial lung diseases.在间质性肺疾病中探寻可治疗的特征。
Respir Res. 2023 Oct 24;24(1):251. doi: 10.1186/s12931-023-02554-8.
4
The genetics of interstitial lung diseases.特发性肺纤维化的遗传学。
Eur Respir Rev. 2019 Sep 25;28(153). doi: 10.1183/16000617.0053-2019. Print 2019 Sep 30.
5
Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).系统性硬化症患者的间质性肺病:基于个体化医学的系统性硬化症相关间质性肺病(SSc-ILD)预测和药物筛选模型。
Front Immunol. 2020 Sep 4;11:1990. doi: 10.3389/fimmu.2020.01990. eCollection 2020.
6
Smoking and interstitial lung diseases.吸烟与间质性肺疾病。
Eur Respir Rev. 2015 Sep;24(137):428-35. doi: 10.1183/16000617.0050-2015.
7
[Chinese expert consensus on multidisciplinary discussion of interstitial lung disease].《间质性肺疾病多学科诊疗中国专家共识》
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Dec 12;46(12):1176-1188. doi: 10.3760/cma.j.cn112147-20230726-00030.
8
Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts.特发性肺纤维化的识别与管理进展:中国专家观点。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241288417. doi: 10.1177/17534666241288417.
9
First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases.间质性肺疾病中可治疗特征的基线患病率及1年随访后的首次报告。
Biomedicines. 2024 May 9;12(5):1047. doi: 10.3390/biomedicines12051047.
10
Update on the diagnosis and classification of ILD.特发性肺纤维化诊断和分类的更新。
Curr Opin Pulm Med. 2013 Sep;19(5):453-9. doi: 10.1097/MCP.0b013e328363f48d.

本文引用的文献

1
Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study.一款针对间质性肺疾病患者的智能手机应用程序的可用性:来自更好理解ILD(RE-BUILD)试点研究登记处的结果。
Respirology. 2025 Feb;30(2):147-157. doi: 10.1111/resp.14874. Epub 2024 Dec 17.
2
The 1-min sit-to-stand test as a screening tool to assess exercise-induced oxygen desaturation in normoxemic people with interstitial lung disease.1 分钟坐站测试作为一种筛选工具,用于评估常压性间质肺疾病患者运动引起的氧减饱和度。
Respir Med. 2024 Oct;232:107748. doi: 10.1016/j.rmed.2024.107748. Epub 2024 Jul 27.
3
Thoracic Society of Australia and New Zealand clinical practice guideline on adult home oxygen therapy.
澳大利亚和新西兰胸科学会成人家庭氧疗临床实践指南。
Respirology. 2024 Sep;29(9):765-784. doi: 10.1111/resp.14793. Epub 2024 Jul 15.
4
Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study : Sleep-disordered breathing treatment in IPF.特发性肺纤维化患者使用 CPAP 和夜间氧疗治疗睡眠呼吸障碍:一项初步研究:IPF 中的睡眠呼吸障碍治疗。
Respir Res. 2024 Jun 18;25(1):247. doi: 10.1186/s12931-024-02871-6.
5
Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis.特发性肺纤维化相关肺动脉高压:系统评价和荟萃分析。
Chest. 2024 Oct;166(4):778-792. doi: 10.1016/j.chest.2024.04.025. Epub 2024 May 29.
6
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness.欧洲呼吸学会关于重症成年呼吸系统疾病患者症状管理的临床实践指南。
Eur Respir J. 2024 Jun 28;63(6). doi: 10.1183/13993003.00335-2024. Print 2024 Jun.
7
Interstitial Lung Disease: A Review.间质性肺疾病:综述。
JAMA. 2024 May 21;331(19):1655-1665. doi: 10.1001/jama.2024.3669.
8
Combined pulmonary fibrosis and emphysema syndrome: the age of majority.合并性肺纤维化和肺气肿综合征:成年期
Eur Respir J. 2024 Apr 4;63(4). doi: 10.1183/13993003.00353-2024. Print 2024 Apr.
9
Association of patient-reported outcome measures with lung function and mortality in fibrotic interstitial lung disease: a prospective cohort study.患者报告结局指标与纤维化间质性肺疾病肺功能及死亡率的关联:一项前瞻性队列研究
ERJ Open Res. 2024 Mar 25;10(2). doi: 10.1183/23120541.00591-2023. eCollection 2024 Mar.
10
Genetic factors for ILD-the path of precision medicine.间质性肺疾病的遗传因素——精准医学之路。
Lancet Respir Med. 2024 May;12(5):350-352. doi: 10.1016/S2213-2600(24)00071-7. Epub 2024 Mar 20.